FOR IMMEDIATE RELEASE: Mobile, Tuscaloosa Counties Represent Major New Business for Rapid Drug Screen KINDERHOOK, N.Y. -- March 20, 2024 -- American Bio Medica Corporation (NASDAQ: ABMC) and its distribution partner CSS Test Inc. today announced the addition of two key community corrections accounts in the state of Alabama. These accounts represent significant potential for ABMC's Rapid Drug Screen® on-site drug test. CSS signed a two-year contract with a one-year renewal option with Mobile County Community Corrections, one of the largest county correction departments in Alabama. Mobile County currently uses certified laboratory or on-site testing, and currently utilizes approximately 83,700 tests per year. "This account is a cornerstone account for community correction in this state, which should lead to increasing sales for CSS in other Alabama community corrections departments," said CSS Test president Michael Chalenski. CSS also recently won the Tuscaloosa County Community Corrections bid. While this contract did not estimate usage, recent ordering patterns have led CSS to estimate sales of 25,000-35,000 tests per year. "It is my belief that (Rapid Drug Screen) is above compare with other products on the market," said L. Daniel Boisot Sr., director of Tuscaloosa County Community Corrections, noting that no RDS results have been challenged in court thus far. ABMC chairman and chief executive officer Gerald A Moore hailed the new contracts as a further strengthening of the ABMC and CSS partnership, and a demonstration of the companies' growing presence in the criminal justice market. In this regard, Moore noted that CSS and ABMC also were recently notified by the State of New Jersey that they had been issued an "intent to award" from the State of New Jersey for a drug testing contract. "We are very pleased with the addition of this new business," said Moore. "This is a great result from our growing partnership with CSS Test, and a reaffirmation of the value our on-site drug tests have in the corrections market." About American Bio Medica Corporation American Bio Medica Corporation is a biotechnology company that develops, manufactures and markets inexpensive, accurate, immunoassay diagnostic test kits, including some of the world's most effective on-site drugs of abuse tests. The company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen, Rapid One®, Rapid Tec® and Rapid Tec Cup test for the presence or absence of drugs of abuse in urine, while OralStat6® tests for the presence or absence of drugs of abuse in saliva. ABMC was recently named among the 2002 Deloitte & Touche Technology Fast 500, a listing of the fastest-growing technology companies in North America. This release may contain forward-looking statements. These
forward-looking statements involve risks and uncertainties that could
cause actual results to differ, and such differences could be
material. Such risks and uncertainties include, but are not limited
to, the following: continued acceptance of the Company's products,
increased levels of competition in our industry, the acceptance of new
products, inherent risks associated with product development and
intellectual property rights, the Company's dependence on key
personnel, third party sales and suppliers. There can be no assurance
that the Company will be successful in addressing such risks and
uncertainties. Investors are strongly encouraged to review the section
entitled "Risk Factors" in the Company's annual report on Form 10-KSB
for the transition period ended December 31, 2001, and quarterly
reports on Form 10-QSB on file with the Securities and Exchange
Commission for a discussion of risks and uncertainties that could
affect operating results and the market price of the Company's common
shares.
Contact: American Bio Medica Corporation Gerald A. Moore, 800/227-1243 Fax: 518/758-8171 Email: gerald@americanbiomedica.com Web: www.americanbiomedica.com
|